Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole

Aqeela Afzal, Sergio Caballero, Stela S. Palii, Simona Jurczyk, Machelle Pardue, Dale Geroski, Henry Edelhauser, Guenther Hochhaus, Moon Kim, Alan Franklin, Gideon Shapiro, Maria B. Grant

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Neovascular ocular diseases as exemplified by proliferative diabetic retinopathy (PDR), exudative age-related macular degeneration (AMD), and retinopathy of prematurity (ROP) are severe diseases affecting all age groups in the US. We asked whether a small molecule, carboxyamidotriazole (CAI) known for its anti-angiogenic and anti-tumor effects and its ability to be administered orally in humans, could have anti-angiogenic effects in ocular in vitro and in vivo angiogenesis models. The anti-proliferative effects of CAI were examined by BrdU incorporation using human retinal and dermal endothelial cells and human pigment epithelial cells. The effect of CAI was determined using the Matrigel tube formation assay. The mouse model of choroidal neovascularization (CNV) initiated by laser rupture of Bruch's membrane was used to quantify in vivo effects of aqueous beta-hydroxypropyl cyclodextrin (bHPCD) formulations of CAI on neovascularization. The pharmacokinetics (PK) of CAI after intravitreal administration of bHPCD-CAI was studied in rabbit. The intravitreal toxicology of bHPCD-CAI was also examined in rat ocular tissue. We observed that CAI treatment of human endothelial cells decreased cell proliferation in a dose-dependent manner. In the in vivo tests bHPCD-CAI treatment reduced choroidal neovascular lesion volume, also in a dose-dependent manner. The intravitreal PK of bHPCD-CAI demonstrated that highly efficacious concentrations of CAI are reached in the vitreous compartment. No ocular toxicology was observed with intravitreous injection of CAI. These studies support the potential of developing intravitreal CAI in an bHPCD ocular formulation for treatment of proliferative retinopathies in humans.

Original languageEnglish (US)
Pages (from-to)320-326
Number of pages7
JournalBrain Research Bulletin
Volume81
Issue number2-3
DOIs
StatePublished - Feb 15 2010
Externally publishedYes

Fingerprint

carboxyamido-triazole
Retinal Neovascularization
Choroidal Neovascularization
Toxicology
Endothelial Cells
Pharmacokinetics
Bruch Membrane

Keywords

  • Angiogenesis
  • Animal model
  • Carboxyamidotriazole
  • Choroidal Neovascularization
  • Endothelial cell
  • Therapy

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Afzal, A., Caballero, S., Palii, S. S., Jurczyk, S., Pardue, M., Geroski, D., ... Grant, M. B. (2010). Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. Brain Research Bulletin, 81(2-3), 320-326. https://doi.org/10.1016/j.brainresbull.2009.08.001

Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. / Afzal, Aqeela; Caballero, Sergio; Palii, Stela S.; Jurczyk, Simona; Pardue, Machelle; Geroski, Dale; Edelhauser, Henry; Hochhaus, Guenther; Kim, Moon; Franklin, Alan; Shapiro, Gideon; Grant, Maria B.

In: Brain Research Bulletin, Vol. 81, No. 2-3, 15.02.2010, p. 320-326.

Research output: Contribution to journalArticle

Afzal, A, Caballero, S, Palii, SS, Jurczyk, S, Pardue, M, Geroski, D, Edelhauser, H, Hochhaus, G, Kim, M, Franklin, A, Shapiro, G & Grant, MB 2010, 'Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole', Brain Research Bulletin, vol. 81, no. 2-3, pp. 320-326. https://doi.org/10.1016/j.brainresbull.2009.08.001
Afzal, Aqeela ; Caballero, Sergio ; Palii, Stela S. ; Jurczyk, Simona ; Pardue, Machelle ; Geroski, Dale ; Edelhauser, Henry ; Hochhaus, Guenther ; Kim, Moon ; Franklin, Alan ; Shapiro, Gideon ; Grant, Maria B. / Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. In: Brain Research Bulletin. 2010 ; Vol. 81, No. 2-3. pp. 320-326.
@article{da20b880271a44878b80825d2f9650d3,
title = "Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole",
abstract = "Neovascular ocular diseases as exemplified by proliferative diabetic retinopathy (PDR), exudative age-related macular degeneration (AMD), and retinopathy of prematurity (ROP) are severe diseases affecting all age groups in the US. We asked whether a small molecule, carboxyamidotriazole (CAI) known for its anti-angiogenic and anti-tumor effects and its ability to be administered orally in humans, could have anti-angiogenic effects in ocular in vitro and in vivo angiogenesis models. The anti-proliferative effects of CAI were examined by BrdU incorporation using human retinal and dermal endothelial cells and human pigment epithelial cells. The effect of CAI was determined using the Matrigel tube formation assay. The mouse model of choroidal neovascularization (CNV) initiated by laser rupture of Bruch's membrane was used to quantify in vivo effects of aqueous beta-hydroxypropyl cyclodextrin (bHPCD) formulations of CAI on neovascularization. The pharmacokinetics (PK) of CAI after intravitreal administration of bHPCD-CAI was studied in rabbit. The intravitreal toxicology of bHPCD-CAI was also examined in rat ocular tissue. We observed that CAI treatment of human endothelial cells decreased cell proliferation in a dose-dependent manner. In the in vivo tests bHPCD-CAI treatment reduced choroidal neovascular lesion volume, also in a dose-dependent manner. The intravitreal PK of bHPCD-CAI demonstrated that highly efficacious concentrations of CAI are reached in the vitreous compartment. No ocular toxicology was observed with intravitreous injection of CAI. These studies support the potential of developing intravitreal CAI in an bHPCD ocular formulation for treatment of proliferative retinopathies in humans.",
keywords = "Angiogenesis, Animal model, Carboxyamidotriazole, Choroidal Neovascularization, Endothelial cell, Therapy",
author = "Aqeela Afzal and Sergio Caballero and Palii, {Stela S.} and Simona Jurczyk and Machelle Pardue and Dale Geroski and Henry Edelhauser and Guenther Hochhaus and Moon Kim and Alan Franklin and Gideon Shapiro and Grant, {Maria B.}",
year = "2010",
month = "2",
day = "15",
doi = "10.1016/j.brainresbull.2009.08.001",
language = "English (US)",
volume = "81",
pages = "320--326",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "2-3",

}

TY - JOUR

T1 - Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole

AU - Afzal, Aqeela

AU - Caballero, Sergio

AU - Palii, Stela S.

AU - Jurczyk, Simona

AU - Pardue, Machelle

AU - Geroski, Dale

AU - Edelhauser, Henry

AU - Hochhaus, Guenther

AU - Kim, Moon

AU - Franklin, Alan

AU - Shapiro, Gideon

AU - Grant, Maria B.

PY - 2010/2/15

Y1 - 2010/2/15

N2 - Neovascular ocular diseases as exemplified by proliferative diabetic retinopathy (PDR), exudative age-related macular degeneration (AMD), and retinopathy of prematurity (ROP) are severe diseases affecting all age groups in the US. We asked whether a small molecule, carboxyamidotriazole (CAI) known for its anti-angiogenic and anti-tumor effects and its ability to be administered orally in humans, could have anti-angiogenic effects in ocular in vitro and in vivo angiogenesis models. The anti-proliferative effects of CAI were examined by BrdU incorporation using human retinal and dermal endothelial cells and human pigment epithelial cells. The effect of CAI was determined using the Matrigel tube formation assay. The mouse model of choroidal neovascularization (CNV) initiated by laser rupture of Bruch's membrane was used to quantify in vivo effects of aqueous beta-hydroxypropyl cyclodextrin (bHPCD) formulations of CAI on neovascularization. The pharmacokinetics (PK) of CAI after intravitreal administration of bHPCD-CAI was studied in rabbit. The intravitreal toxicology of bHPCD-CAI was also examined in rat ocular tissue. We observed that CAI treatment of human endothelial cells decreased cell proliferation in a dose-dependent manner. In the in vivo tests bHPCD-CAI treatment reduced choroidal neovascular lesion volume, also in a dose-dependent manner. The intravitreal PK of bHPCD-CAI demonstrated that highly efficacious concentrations of CAI are reached in the vitreous compartment. No ocular toxicology was observed with intravitreous injection of CAI. These studies support the potential of developing intravitreal CAI in an bHPCD ocular formulation for treatment of proliferative retinopathies in humans.

AB - Neovascular ocular diseases as exemplified by proliferative diabetic retinopathy (PDR), exudative age-related macular degeneration (AMD), and retinopathy of prematurity (ROP) are severe diseases affecting all age groups in the US. We asked whether a small molecule, carboxyamidotriazole (CAI) known for its anti-angiogenic and anti-tumor effects and its ability to be administered orally in humans, could have anti-angiogenic effects in ocular in vitro and in vivo angiogenesis models. The anti-proliferative effects of CAI were examined by BrdU incorporation using human retinal and dermal endothelial cells and human pigment epithelial cells. The effect of CAI was determined using the Matrigel tube formation assay. The mouse model of choroidal neovascularization (CNV) initiated by laser rupture of Bruch's membrane was used to quantify in vivo effects of aqueous beta-hydroxypropyl cyclodextrin (bHPCD) formulations of CAI on neovascularization. The pharmacokinetics (PK) of CAI after intravitreal administration of bHPCD-CAI was studied in rabbit. The intravitreal toxicology of bHPCD-CAI was also examined in rat ocular tissue. We observed that CAI treatment of human endothelial cells decreased cell proliferation in a dose-dependent manner. In the in vivo tests bHPCD-CAI treatment reduced choroidal neovascular lesion volume, also in a dose-dependent manner. The intravitreal PK of bHPCD-CAI demonstrated that highly efficacious concentrations of CAI are reached in the vitreous compartment. No ocular toxicology was observed with intravitreous injection of CAI. These studies support the potential of developing intravitreal CAI in an bHPCD ocular formulation for treatment of proliferative retinopathies in humans.

KW - Angiogenesis

KW - Animal model

KW - Carboxyamidotriazole

KW - Choroidal Neovascularization

KW - Endothelial cell

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=73149124517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73149124517&partnerID=8YFLogxK

U2 - 10.1016/j.brainresbull.2009.08.001

DO - 10.1016/j.brainresbull.2009.08.001

M3 - Article

VL - 81

SP - 320

EP - 326

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 2-3

ER -